Pyrimidines

"Pyrimidines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates.

Descriptor ID	D011743
MeSH Number(s)	D03.383.742
Concept/Terms	Pyrimidines Pyrimidines

Below are MeSH descriptors whose meaning is more general than "Pyrimidines".

Chemicals and Drugs [D]
Heterocyclic Compounds [D03]
Heterocyclic Compounds, 1-Ring [D03.383]
Pyrimidines [D03.383.742]

Below are MeSH descriptors whose meaning is related to "Pyrimidines".

Below are MeSH descriptors whose meaning is more specific than "Pyrimidines".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Pyrimidines" by people in this website by year, and whether "Pyrimidines" was a major or minor topic of these publications.

Bar chart showing 88 publications over 26 distinct years, with a maximum of 8 publications in 2011 and 2017

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1995	1	0	1
1998	1	1	2
2001	0	1	1
2002	1	1	2
2003	0	2	2
2004	1	2	3
2005	0	2	2
2006	3	1	4
2007	3	0	3
2008	1	4	5
2009	3	1	4
2010	4	1	5
2011	3	5	8
2012	2	3	5
2013	3	3	6
2014	2	4	6
2015	2	1	3
2016	0	3	3
2017	5	3	8
2018	1	1	2
2019	1	0	1
2020	1	2	3
2021	0	4	4
2022	0	1	1
2023	1	0	1
2024	2	1	3

Below are the most recent publications written about "Pyrimidines" by people in Profiles.

Abu Rabe D, Chdid L, Lamson DR, Laudeman CP, Tarpley M, Elsayed N, Smith GR, Zheng W, Dixon MS, Williams KP. Identification of Novel GANT61 Analogs with Activity in Hedgehog Functional Assays and GLI1-Dependent Cancer Cells. Molecules. 2024 Jun 28; 29(13).

View in: PubMed
Yaeger R, Uboha NV, Pelster MS, Bekaii-Saab TS, Barve M, Saltzman J, Sabari JK, Peguero JA, Paulson AS, J?nne PA, Cruz-Correa M, Anderes K, Velastegui K, Yan X, Der-Torossian H, Klempner SJ, Kopetz SE. Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRASG12C-Mutated Metastatic Colorectal Cancer. Cancer Discov. 2024 Jun 03; 14(6):982-993.

View in: PubMed
Gladwin MT, Gordeuk VR, Desai PC, Minniti C, Novelli EM, Morris CR, Ataga KI, De Castro L, Curtis SA, El Rassi F, Ford HJ, Harrington T, Klings ES, Lanzkron S, Liles D, Little J, Nero A, Smith W, Taylor JG, Baptiste A, Hagar W, Kanter J, Kinzie A, Martin T, Rafique A, Telen MJ, Lalama CM, Kato GJ, Abebe KZ. Riociguat in patients with sickle cell disease and hypertension or proteinuria (STERIO-SCD): a randomised, double-blind, placebo controlled, phase 1-2 trial. Lancet Haematol. 2024 May; 11(5):e345-e357.

View in: PubMed
Sutar Y, Singh SK, Dhoble S, Mali J, Adams J, Yadavalli T, Date AA, Shukla D. Oral Self-Nanoemulsifying System Containing Ionic Liquid of BX795 Is Effective against Genital HSV-2 Infection in Mice. ACS Infect Dis. 2024 01 12; 10(1):93-106.

View in: PubMed
Strich JR, Tian X, Samour M, King CS, Shlobin O, Reger R, Cohen J, Ahmad K, Brown AW, Khangoora V, Aryal S, Migdady Y, Kyte JJ, Joo J, Hays R, Collins AC, Battle E, Valdez J, Rivero J, Kim IH, Erb-Alvarez J, Shalhoub R, Chakraborty M, Wong S, Colton B, Ramos-Benitez MJ, Warner S, Chertow DS, Olivier KN, Aue G, Davey RT, Suffredini AF, Childs RW, Nathan SD. Fostamatinib for the Treatment of Hospitalized Adults With Coronavirus Disease 2019: A Randomized Trial. Clin Infect Dis. 2022 08 24; 75(1):e491-e498.

View in: PubMed
Rudra S, Shaul E, Conrad M, Patel T, Moore A, Dawany N, Canavan MC, Sullivan KE, Behrens E, Kelsen JR. Ruxolitinib: Targeted Approach for Treatment of Autoinflammatory Very Early Onset Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2022 06; 20(6):1408-1410.e2.

View in: PubMed
Borrero-Garc?a LD, Del Mar Maldonado M, Medina-Vel?zquez J, Troche-Torres AL, Velazquez L, Grafals-Ruiz N, Dharmawardhane S. Rac inhibition as a novel therapeutic strategy for EGFR/HER2 targeted therapy resistant breast cancer. BMC Cancer. 2021 Jun 01; 21(1):652.

View in: PubMed
Strich JR, Ramos-Benitez MJ, Randazzo D, Stein SR, Babyak A, Davey RT, Suffredini AF, Childs RW, Chertow DS. Fostamatinib Inhibits Neutrophils Extracellular Traps Induced by COVID-19 Patient Plasma: A Potential Therapeutic. J Infect Dis. 2021 03 29; 223(6):981-984.

View in: PubMed
Triebwasser MP, Barrett DM, Bassiri H, Bunin N, Elgarten C, Freedman J, Geera AS, Monos D, Lambert MP, Olson T, Seif AE, Paessler M, Petrosa W, Reilly AF, Romberg N, Sullivan KE, Quinn GZ, Behrens E, Teachey DT. Combined use of emapalumab and ruxolitinib in a patient with refractory hemophagocytic lymphohistiocytosis was safe and effective. Pediatr Blood Cancer. 2021 07; 68(7):e29026.

View in: PubMed
Ranganna K, Selvam C, Shivachar A, Yousefipour Z. Histone Deacetylase Inhibitors as Multitarget-Directed Epi-Drugs in Blocking PI3K Oncogenic Signaling: A Polypharmacology Approach. Int J Mol Sci. 2020 Nov 02; 21(21).

View in: PubMed

People

Explore

Similar Concepts

Top Journals